AlphaMeld Corporation
Amit Agrawal serves as the Chief Scientific Officer for the Diagnostics Platform at Danaher Corporation since September 2023, where the focus includes developing an innovation engine for the diagnostics group. Prior to this role, Amit has held various significant positions at Novartis, including Global Head of Data42 and SVP roles in Precision Medicine and Global Drug Development, overseeing large teams and budgets to drive R&D innovation. Previous experiences also include leadership roles at Amgen in Corporate Strategy and Digital Innovation, a brief tenure as COO at Bellerophon Therapeutics, and strategic consulting with McKinsey & Company. Amit's early research achievements include groundbreaking work during postdoctoral studies at MIT and graduate research at Georgia Institute of Technology. Amit holds a Ph.D. in Biomedical Engineering from Georgia Institute of Technology, a Graduate Certificate in Entrepreneurship from the same institution, and dual degrees in Chemistry from the Indian Institute of Technology, Kanpur.
This person is not in any teams
This person is not in any offices
AlphaMeld Corporation
Headquartered in Guilford, CT, AlphaMeld® Corporation (a wholly owned subsidiary of InveniAI LLC) stands as a global frontrunner in the application of AI, machine learning, and generative AI tools, catalyzing innovation throughout drug discovery and development. With a mission to identify and expedite transformative therapies for diseases with unmet medical needs, the company utilizes its cutting-edge AlphaMeld platform to extract valuable insights from petabytes of diverse data sets, propelling the creation of groundbreaking drug programs. The company's pioneering approach is underscored by successful collaborations with industry leaders and drug spinouts, solidifying its position as a trailblazer in the realm of AI-driven drug discovery. About The AlphaMeld® Platform The AlphaMeld platform employs a comprehensive approach to generate testable hypotheses, considering factors such as the ideal mode of pharmacotherapy, disease severity, gene ontology, disease pathways, proteinopathies, standard of care, emerging innovation, and enabling technologies. This is done while factoring in medical, scientific, strategic, and commercial considerations.